Published in Viruses on November 06, 2012
Ebola virus disease. BMJ (2014) 2.63
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother (2014) 1.07
Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop. Viruses (2014) 0.99
A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection. MBio (2015) 0.97
Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty (2014) 0.94
Novel approaches and challenges to treatment of central nervous system viral infections. Ann Neurol (2013) 0.90
Ebola Virus Infection: Overview and Update on Prevention and Treatment. Infect Dis Ther (2015) 0.83
The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target. Future Virol (2015) 0.81
Filoviruses: One of These Things is (not) Like the Other. Viruses (2015) 0.78
Mechanisms of immunity in post-exposure vaccination against Ebola virus infection. PLoS One (2015) 0.78
Neglected filoviruses. FEMS Microbiol Rev (2016) 0.78
From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides. Mol Ther Nucleic Acids (2016) 0.78
Pre-symptomatic diagnosis and treatment of filovirus diseases. Front Microbiol (2015) 0.77
Ebola: history, treatment, and lessons from a new emerging pathogen. Am J Physiol Lung Cell Mol Physiol (2014) 0.75
DNA and RNA derivatives to optimize distribution and delivery. Adv Drug Deliv Rev (2015) 0.75
Therapeutics for postexposure treatment of Ebola virus infection. Future Virol (2015) 0.75
Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother (2015) 0.75
Ebola: Implications and Perspectives. Trans Am Clin Climatol Assoc (2015) 0.75
Ebola: Working Toward Treatments and Vaccines. P T (2015) 0.75
Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques. PLoS Negl Trop Dis (2016) 0.75
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol (2009) 5.35
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev (1997) 4.25
Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med (2010) 3.25
Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl (1996) 2.69
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis (2011) 2.52
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 2.39
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem (2004) 1.90
Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis (2010) 1.84
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A (2011) 1.80
Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release (2006) 1.70
VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54
Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug Chem (2007) 1.42
A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev (1997) 1.37
Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli. J Antimicrob Chemother (2006) 1.36
Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev (1996) 1.35
Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother (2008) 1.31
Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res (2007) 1.30
Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother (2009) 1.26
Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis. J Antimicrob Chemother (2005) 1.16
Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli. Antimicrob Agents Chemother (2005) 1.15
Gene-specific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica serovar typhimurium in pure culture and in tissue culture. Antimicrob Agents Chemother (2006) 1.15
Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers. Antimicrob Agents Chemother (2003) 1.14
Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol (2007) 1.11
Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol (2008) 1.10
Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res (2003) 1.09
Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J Virol (2006) 1.08
HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev (2003) 1.07
Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev (2001) 1.04
Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus. J Gen Virol (2008) 1.01
Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther (2001) 1.01
Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers. Arch Virol (2008) 0.98
Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J Antimicrob Chemother (2008) 0.97
Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology (2008) 0.96
Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs (2003) 0.95
Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther (2006) 0.95
Activation of transgene-specific T cells following lentivirus-mediated gene delivery to mouse lung. Mol Ther (2009) 0.95
Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Methods (2007) 0.94
A morpholino oligomer targeting highly conserved internal ribosome entry site sequence is able to inhibit multiple species of picornavirus. Antimicrob Agents Chemother (2008) 0.91
Inhibition of intracellular growth of Salmonella enterica serovar Typhimurium in tissue culture by antisense peptide-phosphorodiamidate morpholino oligomer. Antimicrob Agents Chemother (2009) 0.89
Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev (2000) 0.89
c-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int (2002) 0.87
Nonhuman primates as models for the discovery and development of ebolavirus therapeutics. Expert Opin Drug Discov (2011) 0.84
Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection. Am J Vet Res (2008) 0.83
Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol (2002) 0.83
Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate (2002) 0.83
Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos (2002) 0.78
Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm Res (2002) 0.78
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med (2010) 3.25
Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis (2003) 3.15
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 2.68
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci U S A (2005) 2.35
In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A (2003) 2.32
Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+ CD25+ cells with characteristics of regulatory T cells. J Immunol (2005) 2.21
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis (2005) 1.82
The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov (2005) 1.79
Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol (2005) 1.78
Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol (2005) 1.69
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. Antimicrob Agents Chemother (2009) 1.66
VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63
Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol (2009) 1.62
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol (2004) 1.58
Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy (2009) 1.53
3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A (2010) 1.52
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res (2008) 1.50
P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J Biol Chem (2002) 1.48
Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol (2010) 1.48
Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem (2006) 1.47
Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J Infect Dis (2004) 1.44
Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med (2004) 1.44
Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine (2005) 1.44
IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol (2013) 1.39
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res (2005) 1.38
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Immunol (2008) 1.38
Anthrax biosensor, protective antigen ion channel asymmetric blockade. J Biol Chem (2005) 1.37
Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun (2003) 1.34
Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J (2007) 1.30
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol (2003) 1.27
Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol (2014) 1.27
Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect (2011) 1.27
Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother (2009) 1.26
Assembly of a functional Machupo virus polymerase complex. Proc Natl Acad Sci U S A (2010) 1.24
Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines (2008) 1.23
Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology (2010) 1.23
Severe encephalitis in cynomolgus macaques exposed to aerosolized Eastern equine encephalitis virus. J Infect Dis (2007) 1.22
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol (2008) 1.22
Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine (2004) 1.19
Association of ebola virus matrix protein VP40 with microtubules. J Virol (2005) 1.18
Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates. Antimicrob Agents Chemother (2010) 1.18
Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity. J Biol Chem (2005) 1.17
Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. J Infect Dis (2002) 1.17
Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. Bioorg Med Chem (2005) 1.16
Analysis of Ebola virus and VLP release using an immunocapture assay. J Virol Methods (2005) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Identification of a small-molecule entry inhibitor for filoviruses. J Virol (2011) 1.14
Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis (2007) 1.13
Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis (2007) 1.13
Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology (2004) 1.13
A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J Med Chem (2007) 1.12
Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res (2011) 1.11
Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol (2008) 1.10
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus. PLoS One (2010) 1.10
Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun (2002) 1.10
Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival. Infect Immun (2006) 1.09
Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res (2011) 1.09
Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. ChemMedChem (2008) 1.09
Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antiviral Res (2011) 1.08
The impact of regulations, safety considerations and physical limitations on research progress at maximum biocontainment. Viruses (2012) 1.08
Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors. J Med Chem (2010) 1.08
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR. Bioorg Med Chem (2010) 1.07
Listeria monocytogenes 10403S HtrA is necessary for resistance to cellular stress and virulence. Infect Immun (2006) 1.07
Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res (2009) 1.06
Development of high-content imaging assays for lethal viral pathogens. J Biomol Screen (2010) 1.06
Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect Immun (2005) 1.06
Humanized mice as a preclinical tool for infectious disease and biomedical research. Ann N Y Acad Sci (2011) 1.04